Document text
Principal Investigator: Helen M. Dooley
Organization: UNIVERSITY OF MARYLAND BALTIMORE
Fiscal Year: 2023
Award: $266,262
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
SARS-CoV-2, a betacoronavirus, is the etiologic agent of the ongoing COVID-19 pandemic. In response,
worldwide efforts have led to the rapid development of multiple vaccine candidates that have shown efficacy in
controlled clinical trials and effectiveness in the general population. Despite these advances, viral variants of
concern (VOC) continue to emerge, while the pandemic potential of future coronavirus zoonotic spillovers
remains high. Thus, the overall aim of our research efforts is to guide pan-coronavirus vaccine research and the
provision of immunotherapeutic molecules with broad specificity for future pandemic prevention. To this end we
will interrogate VNAR nanobody repertoires cloned from nurse sharks that have received sequential
heterologous CoV spike ferritin nanoparticle (SpFN) immunizations, i.e., primed with SARS-CoV-2 SpFN, and
recalled with either SARS-CoV-1 SpFN or MERS-CoV SpFN, to identify broadly conserved, neutralizing
epitopes. Isolated nanobodies will be produced in recombinant form and evaluated for function and specificity
using binding, affinity, and competition mapping assays, followed by viral neutralization, and in vivo protection
studies. Based upon our preliminary studies we anticipate that we will find VNAR nanobodies that can target (i)
pan-sarbecovirus epitopes, (ii) pan-merbecovirus epitopes, and potentially (iii) pan-sarbecovirus-merbecovirus
epitopes. To explore this further we will undertake detailed structural biology studies of our current set of broadly
sarbecovirus-reactive VNARs as well as any newly identified VNARs. Using X-ray crystallography and Cryo-EM
imaging we will determine the binding epitope of each VNAR. This atomic level information will be used to map
cross-neutralizing CoV immune epitopes and provide information that can be used in the design of new
immunogens that will elicit pan-sarbecovirus and pan-merbecovirus protective immune responses.
The proposed research is significant because it will provide unique information that can be used to guide
next generation immunogen design and vaccination strategies for protection against SARS-CoV-2 VOC and
future sarbecovirus and merbecovirus zoonotic spillover events. The novelties of our project are (1) the
immunization of nurse sharks with heterologous and highly immunogenic CoV SpFN molecules to elicit broadly
neutralizing antibody responses; (2) the use of structurally unique VNAR nanobodies to probe sites of
vulnerability on sarbecovirus and merbecovirus spike proteins; (3) utilization of a broad panel of sarbecovirus
and merbecovirus RBD molecules to assess the breadth of recognition for both binding and structural studies;
(4) the combination of cross-functional and long-standing expertise in shark immunology and VNAR
identification, vaccine design and structural biology, and small animal challenge studies.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Affinity><Animals><Antibody Response><Antibody Specificity><Antigen-Antibody Complex><Antigenic Determinants><Antigens><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Baltimore><Binding><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Blood><Blood Reticuloendothelial System><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 virus><Causality><Clinical effectiveness><CoV-2><CoV2><Collaborations><Controlled Clinical Trials><Coronaviridae><Coronavirus><Cryo-electron Microscopy><Cryoelectron Microscopy><Development><Electron Cryomicroscopy><Emerging Communicable Diseases><Emerging Infectious Diseases><Epitopes><Etiology><Ferritin><Foundations><Future><General Population><General Public><Goals><Human><Humoral Immunities><Image><Immune><Immune Complex><Immune response><Immunes><Immunization><Immunize><Immunological response><Immunology><Immunotherapeutic agent><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Maps><Maryland><Merbecovirus><Methods><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle East Respiratory coronavirus><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular><Molecular Interaction><Negative Staining><Nurses><Phage Display><Proteins><Recombinants><Research><Research Institute><Resolution><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sarbecovirus><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Shark><Single Crystal Diffraction><Site><Specificity><Structure><Techniques><Universities><Vaccination><Vaccine Design><Vaccine Research><Viral><Wuhan coronavirus><X Ray Crystallographies><X-Ray Crystallography><X-Ray Diffraction Crystallography><X-Ray/Neutron Crystallography><Xray Crystallography><antibody-based immunity><beta CoV><beta coronavirus><betaCoV><betacoronavirus><causation><corona virus><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus vaccination><cross reactivity><cryo-EM><cryoEM><cryogenic electron microscopy><design><designing><developmental><disease causation><future pandemic><hCoV19><host response><imaging><immune drugs><immune system response><immune-based therapeutics><immunization strategy><immunogen><immunogenic><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><in vivo><innovate><innovation><innovative><medical college><medical schools><molecular recognition><nCoV2><nano particle><nano-sized particle><nanobodies><nanobody><nanoparticle><nanosized particle><neutralizing antibody><next generation><next pandemic><novel><nurse><pan CoV vaccine><pan coronavirus vaccine><panCoV vaccine><pancoronavirus vaccine><pandemic concern><pandemic potential><pandemic prevention><pandemic risk><pandemic threat><prevent pandemics><resolutions><response><school of medicine><sdAb><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><single domain antibodies><spillover event><structural biology><universal CoV vaccine><universal coronavirus vaccine><vaccination against coronavirus><vaccination strategy><vaccine candidate><vaccine-related research><variants of concern><zoonotic CoV><zoonotic coronavirus><zoonotic spillover><β CoV><β coronavirus><βCoV>